Skip Navigation
  

Related Links

(55) Direct Publications in 2007

Burnham

  1. Dynamic autofocus for continuous-scanning time-delay-and-integration image acquisition in automated microscopy. Bravo-Zanoguera, M,E., Laris, C.A., Nguyen, L.K., Oliva, M. & Price, J.H. J. Biomed Opt., 2007, 12(3), 034011.
  2. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Faustin, B., Lartigue, L., Bruey, J.M., Luciano, F., Sergienko, E., Bailly-Maitre, B., Volkmann, N., Hanein, D., Rouiller, I. & Reed, J.C. Mol Cell., 2007, 25(5):713-24.
  3. Chapter 26 the molecular libraries screening center network (MLSCN): Identifying chemical probes of biological systems. Huryn, D. M., & Cosford, N. D. P. Annual Reports in Medicinal Chemistry,2007, 42: 401-416.
  4. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Johnston, P.A., Phillips, J., Shun, T.Y., Shinde, S., Lazo, J.S., Huryn, D. M., Myers, M. C., Ratnikov, B.I., Smith, J.W., Su, Y., Dahl, R., Cosford, N., Shiryaev, S.A., & Strongin, A.Y. Assay and Drug Development Technologies, 2007, 5:737-750.
  5. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors. Stebbins, J. L., Zhang, Z., Chen, J., Wu, B., Emdadi, A., Williams, M. E., Cashman, J., & Pellecchia, M. J. Med Chem., 2007, 50(26), 6607-6617.
  6. A traceless approach for the solid-phase parallel synthesis trisubstituted oxindoles.Xie, J., Sun, J., Zhang, G., Houghten, R.A., & Yu, Y. J Comb Chem, 2007, 9(4):566-568.

Columbia

None

Emory

  1. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. Du, Y., Moulick, K., Rodina, A., Aguirre, J., Felts, S., Dingledine, R., Fu, H. & Chiosis, G. Journal of Biomolecular Screening, 2007, 12, 915-924.
  2. Improved biochemical strategies for targeted delivery of taxoids. Ganesh, T. Bioorg Med Chem, 2007, 15, 3597-3623.
  3. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Sun, A., Chandrakumar, N., Yoon, J-J., Plemper, R.K., & Snyder, J.P. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5199-5203.
  4. Relationship among ligand conformations in solution, in the solid state, and at the Hsp90 binding site: geldanamycin and radicicol. Thepchatri, P., Eliseo, T., Cicero, D.O., Myles, D., & Snyder, J.P. J Am Chem Soc, 2007, 129, 3127-3134.
  5. Automated, quantitative screening assay for antiangiogenic compounds using transgenic Zebrafish. Tran, T.C., Sneed, B., Haider, J., Blavo, D., White, A., Aiyejorun, T., Baranowski, T.C., Rubinstein, A.L., Doan, T.N., Dingledine, R., & Sandberg, E.M. Cancer Research, 2007, 67, 11386-11392.

NCGC

  1. HTS technologies to facilitate chemical genomics. Auld, D.S., Inglese, J., Jadhav, A., Austin, C.P., Sittampalam, G.S., Montrose-Rafizadeh, C., Mcgee, J.E., & Iversen, P.W. European Pharma. Review, 2007, 2: 53-63.
  2. A Cell-Based Assay for IKBa Stabilization Using Two-Color Dual Luciferase-Based Sensor. Davis, R.E., Zhang, Y., Southall, N., Staudt, L.M., Austin, C.P., Inglese, J., & Auld, D.S. Assay and Drug Development Technologies, 2007, 5: 85-103.
  3. A High-throughput Screen for Aggregation-based inhibition in a Large Compound Library. Feng, B.Y, Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B.K., & Austin, C.P. J. Med. Chem, 2007, 50: 2385-2390.
  4. Differentiating Alzheimer disease-associated aggregates with small molecules. Honson, N. S., Johnson, R. L., Huang, W., Inglese, J., Austin, C.P., & Kuret, J. Neurobiology of Disease, 2007, 28(3), 251-260.
  5. N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Huang, W., Zheng, W., Urban, D.J., Inglese, J., Sidransky, E., Austin, C.P., & Thomas, C.J. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5783-5789.
  6. High-throughput screening assays for the identification of chemical probes. Inglese, J., Johnson, R.L., Simeonov, A., Xia, M., Austin, C.P., & Auld, D.S. Nature Chemical Biology, 2007, 3: 466-479.
  7. Reporting data from high-throughput screening of small-molecule libraries. Inglese, J., Shamu, C.E., & Guy, R.K. Nature Chemical Biology, 2007, 3: 438-441.
  8. Distinctive Inhibition of O-GlcNAcase Isoforms by an alpha-GlcNAc Thiolsulfonate. Kim, E., Amorelli, B., Abdo, M., Thomas, C., Love, D., Knapp, S., Hanover, J. J Am Chem Soc., 2007, 129(48): 14854-14855.
  9. Evaluation of micro-parallel liquid chromatography as a method for HTS-coupled actives verification. Simeonov, A., Yasgar, A., Klumpp, C., Zheng, W., Shafqat, N., Oppermann, U., Austin, C.P., & Inglese, J. Assay and Drug Development Technologies, 2007, 5, 815-824.
  10. Synthesis of substituted 2-phenylhistamines via a microwave promoted Suzuki coupling. Skoumbourdis, A.P., Moore, S., Landsman, M., & Thomas, C.J. Tetrahedron Letters, 2007, 48, 9140-9143.
  11. Bidirectional, Iterative Approach to the Structural Delineation of the Functional Chemoprint in GPR40 for Agonist Recognition. Tikhonova, I., Sum, C., Neumann, S., Thomas, C., Raaka, B. Costanzi, S., Gershengorn, M. J Med Chem., 2007, 50(13):2981-2989.
  12. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Zheng, W., Padla, K., Urban, D.J., Jadhav, A., Goker-Alpan, O., Simeonov, A., Goldin, E., Auld, D., LeMarca, M.E., Inglese, J., Austin, C.P., & Sidransky, E. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104: 13192-13197.

New Mexico

  1. G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17b -Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells.Albanito, L., Madeo, A., Lappano, R., Vivacqua, A., Rago, V., Carpino, A., Oprea, T., Prossnitz, E., Musti, A., Ando, S., & Maggiolini, M. Cancer Res, 2007, 67:1859-1866.
  2. Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen. Ariazi, E.A., Leitao, A., Oprea, T.I., Chen, B., Louis, T., Betucci, A.M., Sharma, C.G.N., Gill, S.D., Kim, H.R., Shupp, H.A., Pyle, J.R., Madrack, A., Donato A.L., Cheng, D., Paige, J.R., & Jordan, V.C. Molecular Cancer Therapeutics, 2007, 11:2817-2827.
  3. Some mechanistic insights into GPCR activation from detergent-solubilized ternary complexes on beads. Buranda, T., Waller, A., Wu, Y., Simons, P.C., Biggs, S., Prossnitz, E.R., & Sklar, L.A. Advanced Protein Chemistry, 2007, 74:95-135.
  4. High Throughput Cytotoxicity Screening by Propidium Iodide Staining. Edwards, B., Ivnitski-Steele, I., Young, S., Salas, V.,.Sklar, L. Current Protocols in Cytometry, 2007, Chapter 9.
  5. High Throughput Flow Cytometry for Drug Discovery. Edwards, B., Young, S., Saunders, M., Bologa. C,, Oprea. T,, Ye, R., Prossnitz, E., Graves, S., & Sklar, L. Expert Opin Drug Discov., 2007, 2:685-696.
  6. High content screening: flow cytometry analysis. Edwards, B., Young, S., Ivnitski-Steele, I., Ye, R., Prossnitz, E., & Sklar, L. In: P. A. Clemons, N. J. Tolliday, and B. K. Wagner (eds.), Cell Based Assays in High-Throughput Screening. Totowa, NJ: Humana Press, Inc., in press, 2007.
  7. Ligand-based virtual screening by novelty detection with self-organizing maps. Hristozov, D. P., Oprea, T.I., & Gasteiger, J.J. Chem. Inf. Model., 2007, 47:2044-2062.
  8. Open, reconfigurable cytometic acquisition system: ORCAS.Naivar, M.A., Parson, J.D., Wilder, M.E., Habbersett, R.C., Edwards, B.S.,Sklar, L., Nolan, J.P., Graves, S.W., Martin, J.C., Jett, J.H., & Freyer, J.P. Cytometry Part A, 2007, 71:915-924.
  9. Lead-like, drug-like or “Pub-like”: how different are they? Oprea, T. I., Allu, T.K, Fara, D.C., Rad, R.F., Ostopovici, L., & Bologa, C.G. J Comput Aided Mol Des, 2007, 21.
  10. Systems chemical biology. Oprea, T. I., Tropsha, A., Faulon, J.L., Rintou, M.D. Nat Chem Biol, 2007, 3:447-450.
  11. GPR30: A G protein-coupled receptor for estrogen. Prossnitz, E. R., Arterburn, J.B., & Sklar, L.A. Mol Cell Endocrinol, 2007, 265-266.
  12. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30.Revankar, C.M., Mitchell, H.D., Field, A.S., Burai, R., Corona, C., Ramesh, C., Sklar, L.A., Arterburn, J.B., & Prossnitz, E.R. ACS Chemical Biology, 2007, 2: 536-544.
  13. Duplexed, bead-based competitive assay for inhibitors of protein kinases. Simons, P.C., Young, S.M., Gibaja, V., Lee, W-C., Josiah, S., Edwards, B.S., & Sklar, L.A. Cytometry Part A, 2007, 71, 451-459.
  14. Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening. Sklar. L.A., Carter, M.B., Edwards, B.S. Current Opinion in Pharmacology, 2007, 7, 527-534.
  15. Rapid-mix flow cytometry measurements of subsecond regulation of G protein-coupled receptor ternary complex dynamics by guanine nucleotides. Wu, Y., Buranda, T., Simons, P.C., Lopez, G.P., McIntire, W.E., Garrison, J.C., Prossnitz, E.R., & Sklar, L.A. Analytical Biochemistry, 2007, 371:10-20.
  16. The development of quantum dot calibration beads and quantitative multicolor bioassays in flow cytometry and microscopy. Wu, Y., Campos, S.K., Lopez, G.P., Ozbun, M.A., Sklar, L.A., & Buranda, T. Anal Biochem, 2007, 364:180-192.
  17. Spectroscopic characterization of streptavidin functionalized quantum dots. Wu, Y., Lopez, G.P., Sklar, L.A., & Buranda, T. Anal Biochem, 2007, 364:194-203.

Penn

  1. Methods for mapping protease specificity. Diamond, S.L. Current Opinion in Chemical Biology, 2007, 11:46-51.
  2. Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: The confounding effects of DTT and cysteine in biological assays. Myers, M. C., Napper, A.D., Motlekar, N., Shah, P.P., Chiu, C.H., Beavers, M.P., Diamond, S.L., Huryn, D.M., & Smith, III., A.B. Bioorg Med Chem Lett, 2007, 17:4761-4766.

Pittsburgh

  1. Synthesis and Biological Activity of a Focused Library of Mitogen-activated Protein Kinase Phosphatase Inhibitors. Arnold, D. M., Foster, C., Huryn, D. M., Lazo, J. S., Johnston, P.A., &n Wipf, P. Chemical Biology & Drug Design, 2007, 69:23-30.
  2. Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Johnston, P.A., Foster, C.A., Shun, T.Y., Skoko, J.J., Shinde, S., Wipf, P., & Lazo, J.S. Assay and Drug Development Technologies, 2007, 5:319-332.
  3. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Johnston, P.A., Phillips, J., Shun, T.Y., Shinde, S., Lazo, J.S., Huryn, D. M., Myers, M. C., Ratnikov, B.I., Smith, J.W., Su, Y., Dahl, R., Cosford, N., Shiryaev, S.A., & Strongin, A.Y. Assay and Drug Development Technologies, 2007, 5:737-750.
  4. Building a pharmacological lexicon: small molecule discovery in academia. Lazo, J. S., Brady, L., & Dingledine, R. Molecular Pharmacoogy, 2007, 72:1-17.
  5. Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboamide library. Lazo, J.S., Skoko, J.J., Werner, S., Mitasev, B., Bakan, A., Koizumi, F., Yellow-Duke, A., Bahar, I., & Brummond, K.M. Journal of Pharmacology and Experimental Therapeutics, 2007, 322:940-947.
  6. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1. Sharlow, E.R., Leimgruber, S., Shung, T.Y., & Lazo, J.S. Assay and Drug Development Technologies, 2007, 5:723-735.
  7. Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. Vogt, A., & Lazo, J.S. Methods, 2007, 42: 268-277.

Scripps

  1. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. Don, A.S., Martinez-Lamenca, C., Webb, W.R., Proia, R.L., Roberts, E., & Rosen, H. Biological Chemistry, 2007, 282:15833-15842.
  2. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Feng, Y., Cameron, M.D., Frackowiak, B., Griffin, E., Lin, L., Ruiz, C., Schröter, T. & LoGrasso, P. Bioorg Med Chem Lett., 2007, 17(8):2355-2360.
  3. Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics. Gonzalez-Cabrera, P.J., Hla, T., & Rosen., H. Journal of Biological Chemistry, 2007, 282:7254-7264.
  4. Application of B-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Lee, H-K., Brown, S.J.,  Rosen, H., & Tobias, P.S. Molecular Pharmacology, 2007, 72:868-875.
  5. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Rosen, H., Sanna, M.G., Calahan, S.M., & Gonzalez-Cabrera, P.J. Trends in Immunology, 2007, 28:102-107.

Southern Research Institute

  1. A Successful LIMS Implementation: Case Study at Southern Research Institute. Rasmussen, L., Maddox, C.B., Harten, B., & White, E. L. J. Assoc. Lab. Automation, 2007, 12: 384-390.

Vanderbilt

None